1. At a Glance – Pharma’s Quiet Comeback Kid?
₹1,02,698 crore market cap. ₹2,247 stock price. P/E 20.6. ROCE 21.3%. ROE 20.6%. And then comes the mic-drop moment — Q3 FY26 profit up 76% YoY and operating margin sitting at a royal 32%.
Ladies and gentlemen, Lupin Limited just posted its strongest quarter in recent memory.
Quarterly sales: ₹7,168 crore.
Quarterly PAT: ₹1,181 crore.
Quarterly EPS: ₹25.73.
This is not “chalta hai” pharma growth. This is “US generic beast woke up” growth.
Return over 3 months? 9.72%.
5-year stock CAGR? 17%.
Profit CAGR (5 yrs)? 55%.
But here’s the real masala:
- EBITDA margin guidance upgraded to 27–28% for FY26.
- US business hit record $350 million quarter.
- Biosimilars finally stepping into the ring.
- Net cash position strengthened dramatically.
Question is — is this a sustainable transformation or just a blockbuster quarter boosted by settlements and seasonality?
Let’s dissect.
2. Introduction – The Pharma Rollercoaster
If Indian pharma were a Bollywood franchise, Lupin would be that actor who had a golden 2000s phase, then disappeared for a while, and suddenly came back with a six-pack and better scripts.
From regulatory issues in 2019–20 to successful inspections in FY22… from weak US pricing to now record US revenues… this is a company that has clearly gone through corporate therapy.
Headquartered in Mumbai, Lupin operates in over 100 countries. It’s not a “one geography, one product” story. It’s a global generics + biosimilars + injectables + respiratory + specialty cocktail.
In Q3 FY26:
- Revenue touched ₹7,168 crore (24% YoY growth).
- EBITDA margin expanded to 31%+.
- Gross margin jumped to 73.5%.
Gross margin at 73.5% in generics pharma? That’s premium territory.
Meanwhile:
- India grew modestly.
- US grew explosively.
- Emerging markets surged.
- Biosimilar pegfilgrastim got approved.
- Mirabegron settlement clarified earnings visibility till 2027.
So are we looking at structural margin expansion or peak cycle profits?
Let’s go deeper.
3. Business Model – WTF Do They Even Do?
Lupin does three big things:
- Generic formulations
- APIs (Active Pharmaceutical Ingredients)
- Biosimilars & complex generics
In simple words: they copy expensive drugs legally once patents expire, manufacture them at scale, and sell them cheaper.
But here’s where it gets interesting.
US Business
- 3rd largest generic company in the US by prescriptions.
- 457 ANDAs filed.
- 297 approvals.
- 53 First-to-File opportunities.
US contributes 38%+ of sales mix. That’s the real profit engine.
India Business
- Ranked 6th by sales.
- 3 brands in Top 100.
- Chronic share ~67%.
- 11,000+ sales force.
Biosimilars
Now this is the spicy part.
Pegfilgrastim biosimilar approved.
Ranibizumab positive CHMP opinion.
Pipeline includes Aflibercept, Etanercept, Mepolizumab.
Biosimilars are like generics but for complex biologic drugs. Higher margin, higher barrier, higher reward.
So Lupin is evolving from:
“Tablet factory” → “Complex injectables + respiratory + biosimilar specialist”.
Is this transformation real or aspirational PowerPoint?
Let’s check the numbers.
4. Financials Overview – The Hard Evidence
Q1 FY26 EPS: ₹26.69
Q2 FY26 EPS: ₹32.36
Q3 FY26 EPS: ₹25.73
Average = (26.69 + 32.36 + 25.73) / 3 = ₹28.26
Annualised
